CURRENT PE RATIOS DRIVEN BY NEW PRODUCT LINES
All these companies PE Ratios are BEING DRIVEN TODAY by their Covid19 Rapid test sale for both POC and At Home.
ALSO IMPORTANT TO REMEMBER. 2 YEARS AGO THERE WERE NO COVID TEST KITS, SO THIS IS ADDED REVENUE TO ALL THESE COMPANIES. AND ITS BIG REVENUES THAT ACCELERATE THEIR GROWTH
Abbott Laboratories - P/E Ratio: 30.6. (Feb 28, 2022)
Qiagen -P/E Ratio: 21.94. (March 2, 2022)
Diasorin - P/E Ratio: 24.80 (March 2, 2022)
Benton Dickensian - P/E Ratio: 47.18. (Feb 25, 2022)
Celltrion - P/E Ratio: 43.31. (March 03,2022)
OVERALL Medical Products industry - P/E Ratio: 23.55
January 26, 2022- Abbott Q4 revenue beats estimates on demand for COVID-19 tests
https://www.medtechdive.com/news/abbott-q4-revenue-beats-estimates-on-demand-for-covid-19-tests-company-war/617749/
February 17, 2022 -QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
Revenue for COVID-19 products was $511.8 million, versus $405.3 million in the fourth quarter of 2020.
https://ir.quidel.com/news/news-release-details/2022/Quidel-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results/default.aspx
February 8, 2022. - QIAGEN beats outlook for fourth quarter and full-year 2021Net sales for Q4 2021 rose 2% (+4% CER) to $582 million from Q4 2020, well ahead of the outlook for a 9% CER decline. Sales were driven by high demand for COVID-19 test products and confirmed good trends in the non-COVID portfolio.
https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2022/QIAGEN-beats-outlook-for-fourth-quarter-and-full-year-2021-delivers-22-CER-full-year-sales-growth-from-non-COVID-products/default.aspx 0